Clinical Applications of Hepatobiliary MR Contrast Agents



Modern hepatocellular-specific MR contrast agents such as gadoxetic acid are an important adjunct to conventional extracellular contrast material in MRI examinations of the liver. They allow not only evaluation of vascular structures and early dynamic contrast kinetics but are also able to determine the presence or absence of functioning hepatocytes. In addition, the high biliary excretion rate of 50% allows a true T1 cholangiopancreatography phase with improved characterization of biliary abnormalities and leaks.


Focal Nodular Hyperplasia Focal Liver Lesion Hepatobiliary Phase Dysplastic Nodule Hepatocellular Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200(1):59–67PubMedGoogle Scholar
  2. 2.
    Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40(11):715–724PubMedCrossRefGoogle Scholar
  3. 3.
    Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57(2):421–429PubMedCrossRefGoogle Scholar
  4. 4.
    Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM (2011) Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. AJR Am J Roentgenol 196(1):W18–W24PubMedCrossRefGoogle Scholar
  5. 5.
    Colagrande S, Mazzoni LN, Mazzoni E, Pradella S (2012) Effects of gadoxetic acid on quantitative diffusion-weighted imaging of the liver. J Magn Reson ImagingGoogle Scholar
  6. 6.
    Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW (2010) Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 20(5):1052–1060PubMedCrossRefGoogle Scholar
  7. 7.
    Ringe KI, Gupta RT, Brady CM et al (2010) Respiratory-triggered three-dimensional T2-weighted MR cholangiography after injection of gadoxetate disodium: is it still reliable? Radiology 255(2):451–458PubMedCrossRefGoogle Scholar
  8. 8.
    Kim KA, Kim MJ, Park MS et al (2010) Optimal T2-weighted MR cholangiopancreatographic images can be obtained after administration of gadoxetic acid. Radiology 256(2):475–484PubMedCrossRefGoogle Scholar
  9. 9.
    Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29(6):1725–1748PubMedCrossRefGoogle Scholar
  10. 10.
    Asbach P, Warmuth C, Stemmer A et al (2008) High spatial resolution T1-weighted MR imaging of liver and biliary tract during uptake phase of a hepatocyte-specific contrast medium. Invest Radiol 43(11):809–815PubMedCrossRefGoogle Scholar
  11. 11.
    Huppertz A, Balzer T, Blakeborough A et al (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230(1):266–275PubMedCrossRefGoogle Scholar
  12. 12.
    Tamada T, Ito K, Yamamoto A et al (2011) Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 196(4):824–830PubMedCrossRefGoogle Scholar
  13. 13.
    Gupta RT, Marin D, Boll DT et al (2012) Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. Eur J Radiol 81(10):2457–2462PubMedCrossRefGoogle Scholar
  14. 14.
    Motosugi U, Ichikawa T, Onohara K et al (2011) Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging. Invest Radiol 46(6):359–365PubMedCrossRefGoogle Scholar
  15. 15.
    Goshima S, Kanematsu M, Watanabe H et al (2010) Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. AJR Am J Roentgenol 195(4):941–946PubMedCrossRefGoogle Scholar
  16. 16.
    Hussain SM, Terkivatan T, Zondervan PE et al (2004) Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 24(1):3–17; discussion 8–9PubMedCrossRefGoogle Scholar
  17. 17.
    Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C (1999) Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 23(12):1441–1454PubMedCrossRefGoogle Scholar
  18. 18.
    Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43(7):504–511PubMedCrossRefGoogle Scholar
  19. 19.
    Trotter JF, Everson GT (2001) Benign focal lesions of the liver. Clin Liver Dis 5(1):17–42, vGoogle Scholar
  20. 20.
    Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A (2001) Hepatic adenomas: imaging and pathologic findings. Radiographics 21(4):877–892; discussion 92–4PubMedCrossRefGoogle Scholar
  21. 21.
    Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D (2007) Elective surgery for benign liver tumours. Cochrane Database Syst Rev 1, CD005164PubMedGoogle Scholar
  22. 22.
    Denecke T, Steffen IG, Agarwal S et al (2012) Appearance of hepatocellular adenomas on gadoxetic acid-enhanced MRI. Eur Radiol 22(8):1769–1775PubMedCrossRefGoogle Scholar
  23. 23.
    Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262(2):520–529PubMedCrossRefGoogle Scholar
  24. 24.
    Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31(6):1547–1568PubMedCrossRefGoogle Scholar
  25. 25.
    Choi JY, Choi JS, Kim MJ et al (2010) Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent. J Magn Reson Imaging 31(3):571–578PubMedCrossRefGoogle Scholar
  26. 26.
    Kim A, Lee CH, Kim BH et al (2012) Gadoxetic acid-enhanced 3.0T MRI for the evaluation of hepatic metastasis from colorectal cancer: metastasis is not always seen as a “defect” on the hepatobiliary phase. Eur J Radiol 81(12):3998–4004PubMedCrossRefGoogle Scholar
  27. 27.
    Ha S, Lee CH, Kim BH et al (2012) Paradoxical uptake of Gd-EOB-DTPA on the hepatobiliary phase in the evaluation of hepatic metastasis from breast cancer: is the “target sign” a common finding? Magn Reson Imaging 30(8):1083–1090PubMedCrossRefGoogle Scholar
  28. 28.
    Sofue K, Tsurusaki M, Tokue H, Arai Y, Sugimura K (2011) Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 21(11):2336–2343PubMedCrossRefGoogle Scholar
  29. 29.
    Hussain SM, Reinhold C, Mitchell DG (2009) Cirrhosis and lesion characterization at MR imaging. Radiographics 29(6):1637–1652PubMedCrossRefGoogle Scholar
  30. 30.
    Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261(3):834–844PubMedCrossRefGoogle Scholar
  31. 31.
    Kondo F (2011) Assessment of stromal invasion for correct histological diagnosis of early hepatocellular carcinoma. Int J Hepatol 2011:241652PubMedGoogle Scholar
  32. 32.
    Huppertz A, Haraida S, Kraus A et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology 234(2):468–478PubMedCrossRefGoogle Scholar
  33. 33.
    Saito K, Kotake F, Ito N et al (2005) Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4(1):1–9PubMedGoogle Scholar
  34. 34.
    Bartolozzi C, Crocetti L, Lencioni R, Cioni D, Della Pina C, Campani D (2007) Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol 17(10):2519–2530PubMedCrossRefGoogle Scholar
  35. 35.
    Kitao A, Zen Y, Matsui O et al (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging—correlation with molecular transporters and histopathologic features. Radiology 256(3):817–826PubMedCrossRefGoogle Scholar
  36. 36.
    Yamamoto A, Tamada T, Sone T, Higashi H, Yamashita T, Ito K (2010) Gd-EOB-DTPA-enhanced magnetic resonance imaging findings of nondiffuse fatty change of the liver. J Comput Assist Tomogr 34(6):868–873PubMedCrossRefGoogle Scholar
  37. 37.
    Fayad LM, Holland GA, Bergin D et al (2003) Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography. J Magn Reson Imaging 18(4):449–460PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Radiology and Medical ImagingUniversity of Virginia Medical CenterCharlottesvilleUSA

Personalised recommendations